130 related articles for article (PubMed ID: 9434462)
1. [Clinical trial of AY4166].
Kikuchi M
Nihon Rinsho; 1997 Nov; 55 Suppl():164-70. PubMed ID: 9434462
[No Abstract] [Full Text] [Related]
2. [Preclinical studies of AY4166 (A-4166)].
Kondo N
Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
[No Abstract] [Full Text] [Related]
3. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
Nagashima K; Inagaki N
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):737-41. PubMed ID: 19472523
[No Abstract] [Full Text] [Related]
4. [NAVIGATOR trial (nateglinide)].
Tsujii S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():483-7. PubMed ID: 15779426
[No Abstract] [Full Text] [Related]
5. Nateglinide.
Dunn CJ; Faulds D
Drugs; 2000 Sep; 60(3):607-615; discussion 616-7. PubMed ID: 11030470
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.
Iwase M; Iino K; Doi Y; Asano T; Iida M
Diabetes Res Clin Pract; 2008 Dec; 82(3):e19-22. PubMed ID: 18849086
[TBL] [Abstract][Full Text] [Related]
7. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
8. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
9. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Ikenoue T; Kondo N
Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
[TBL] [Abstract][Full Text] [Related]
11. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag JB; Walter YH; Nedelman JR; McLeod JF
Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
[TBL] [Abstract][Full Text] [Related]
12. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
13. Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
Kotapati S
Conn Med; 2002 May; 66(5):269-72. PubMed ID: 12071108
[No Abstract] [Full Text] [Related]
14. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Mari A; Gastaldelli A; Foley JE; Pratley RE; Ferrannini E
Diabetes Care; 2005 May; 28(5):1132-8. PubMed ID: 15855578
[TBL] [Abstract][Full Text] [Related]
15. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
16. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
17. Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes.
Ai M; Tanaka A; Ogita K; Shimokado K
Diabetes Care; 2006 May; 29(5):1180. PubMed ID: 16644666
[No Abstract] [Full Text] [Related]
18. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide for type 2 diabetes.
Med Lett Drugs Ther; 2001 Apr; 43(1101):29-30. PubMed ID: 11283474
[No Abstract] [Full Text] [Related]
20. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
